Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro: Evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors

Neuropharmacology

Volumn 36, Issue 1, 1997, Pages 39-50

  Rao, T S ^a   Correa, L D ^a   Lloyd, G K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DMPP; lobeline; neuronal nicotinic acetylcholine receptors; NMDA; striatal acetylcholine

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; CYTISINE; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; LOBELINE; MECAMYLAMINE; METHYLLYCACONITINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; SULPIRIDE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; DIMETHYLPHENYLPIPERAZINIUM IODIDE; EXCITATORY AMINO ACID AGONISTS; HIPPOCAMPUS; LOBELINE; N-METHYLASPARTATE; NEOSTRIATUM; NICOTINIC AGONISTS; RATS; RECEPTORS, NICOTINIC;

EID: 0031057408     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00162-1     Document Type: Article

References (35)

1. Aizenman E., Lian-Hong T., Reynolds I.J. Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551:1991;355-357.
2. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
3. Akaike N., Harata N., Tateishi N. Modulatory action of cholinergic drugs on N-methyl-D-aspartate response in dissociated rat nucleus basalis of meynert neurons. Neurosci. Lett. 130:1991;243-247.
4. 3H]-methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253:1994;261-267.
5. 3H]-acetylcholine release. In: Neurotransmitter Interactions in Basal Ganglia (Sandler M., Feurstein C. and Scatton B., Eds), pp. 111-120. Raven Press, New York.
6. Bartholini G., Lloyd G.K., Stadler H. Dopaminergic regulation of cholinergic neurons in the striatum: relation to Parkinsonism. Adv. Neurol. 5:1974;11-14.
7. Bhat R.V., Turner S.L., Selvaag S.R., Marks M.J., Collins A.C. Regulation of brain nicotinic receptors by chronic nicotinic infusion. J. Neurochem. 56:1991;1932-1939.
8. Clarke P.B.S., Chaudiau I., el-Bizri I., Boska P., Quick M., Esplin B.A., Capek R. The pharmacology of the nicotinic antagonist chlorisondamine investigated in rat brain and autonomic ganglia. Br. J. Pharmacol. 111:1994;397-405.
9. Clarke P.B.S., Reuben M. Pharmacological comparison of nicotine-evoked release of striatal dopamine and hippocampal noradrenaline from superfused synaptosomes. Soc. Neurosci. 21:1995;721-729.
10. 3H]-dopamine release. Br. J. Pharmacol. 117:1996;595-606.
11. 3H]-MK-801 to brain membranes, but not via the stimulation of high-affinity nicotinic receptors. Brain Res. 524:1990;319-321.
12. Gurney A.M., Rang H.P. The channel blocking action of methonium compounds on rat submandibular ganglion cells. Br. J. Pharmacol. 82:1984;623-642.
13. Fudala P.J., Iwamoto E.T. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol. Biochem. Behav. 25:1986;1041-1049.
14. Hasegawa M., Kinoshita H., Amano M., Hasegawa T., Kameyama T., Nabeshima T. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis. Neurosci. Lett. 150:1993;53-66.
15. Holbach H.J., Lindmar R., Loffelholtz K. DMPP and the adrenergic nerve terminal: mechanisms of noradrenaline release from vesicular and extravesicular compartments. Naunyn-Schmiedberg's Arch. Pharmacol. 300:1977;131-138.
16. Lehmann J., Langer S.Z. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals. Neuroscience. 10:1983;1105-1120.
17. 3H]-acetylcholine from rat striatal slices. Brain Res. 252:1982;77-89.
18. Marin P., Maus M., Desagher S., Glowinski J., Premont J. Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuro-Report. 5:1994;1977-1980.
19. Marks M.J., Collins A.C. Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quiniclinidyl benzilate. Mol. Pharmacol. 22:1982;554-564.
20. McGeer E.G., McGeer P.L., Singh K. Kainate induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 139:1978;381-383.
21. O'Dell T.J., Christensen B.N. Mecamylamine is a selective non-competitive antagonist of NMDA and ASP-induced currents in horizontal cells dissociated from catfish retina. Neurosci. Lett. 94:1988;93-98.
22. Rao T.S., Correa L.D., Reid R., Lloyd G.K. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay. Neuropharmacology. 35:1996;393-405.
23. Ramoa A.S., Alkondon M., Arcava Y., Irons J., Lunt G.G., Deshpande S.S., Wonnacott S., Aronstam, Albuquerque E.X. The anticonvulsant MK-801 interacts with peripheral and central nicotinic aceylcholine receptor ion channels. J. Pharmacol. Exp. Ther. 254:1990;71-82.
24. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 29:1990;619-624.
25. Romano C. Nicotine action on rat colon. J. Pharmacol. Exp. Ther. 217:1981;828-833.
26. Sacaan A.I., Dunlop J.L., Lloyd G.K. Pharmacological characterization of neuronal acetylcholine-gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharmacol. Exp. Ther. 274:1995;224-230.
27. Sacaan A.I., Menzaghi F., Dunlop J.L., Correa L.D., Whelan K.D., Lloyd G.K. Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats. J. Pharmacol. Exp. Ther. 276:1996;509-515.
28. Sacaan A.I., Menzaghi F.M., Reid R.T., Santori E.M., Correa L.D., Whelan K.T., Lloyd G.K. and Rao T.S. (1996b) Lobeline: an atypical neuronal nicotinic acetylcholine receptor (NAChR) agonist. Soc. Neurosci. Abs. 21(602.12): 1523.
29. Shoaib M., Stolerman I.P. MK-801 attenuates behavioral adaptation to chronic nicotine administration in rats. Br. J. Pharmacol. 105:1992;514-515.
30. Shoaib M., Benwell M.E.M., Akbar M.T., Stolerman I.P., Balfour D.J.K. Behavioral and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. 111:1994;1073-1080.
31. 3H]-(1-[1-(2-thienyl)cyclohexyl-piperidine) binding in rat hippocampus. Synapse. 3:1989;129-135.
32. Sofroniew M.V., Pearson R.C.A. Degeneration of cholinergic neurons in the basal nucleus following kainic acid or N-methyl-D-aspartic acid application to the cerebral cortex in the rat. Brain Res. 339:1985;186-190.
33. Stolerman I.P., Garcha H.S., Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology. 117:1995;430-437.
34. Williams M., Robinson J.L. Binding of nicotinic-cholinergic antagonist, dihydro-beta erythroidine (DBE) to rat brain tissue. J. Neurosci. 4:1984;2906-2911.
35. Wonnacott S., Albuquerque E.X., Betrand D. Methyllycaconitine: a new probe that discriminates between nicotinic acetylcholine receptor subclasses. Meth. Neurosci. 12:1993;263-275.